Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Daily vs Twice Daily Raltegravir in Treatment-Naïve HIV
NCT00745823Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Primary completion
- Oct 2010
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of raltegravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co.. Started Sep 2008; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00745823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00745823.